Stockwinners Market Radar for March 01, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:02 EST EchoStar director buys 20K shares of common stock - In a regulatory filing, EchoStar disclosed that its Chief Strategy Officer Anders Johnson bought 20K shares of common stock on February 25th in a total transaction size of $469K, boosting his stake by 653%.

18:54 EST TransMedics announces scheduling of OCS Heart FDA AdCom meeting - TransMedics Group announced that the FDA's Office of Health Technology 2 has communicated its intent to hold a Circulatory Systems Device Advisory Panel meeting on April 6, 2021 to review TransMedics' premarket approval application for the OCS Heart System. "We are looking forward to this important milestone and to hopefully achieving a positive conclusion of the FDA's review process of our OCS Heart PMA application," said Waleed Hassanein, M.D., CEO.

18:36 EST Ready Capital declares 30c per share prorated dividend - Ready Capital announced that its board of directors declared a prorated dividend of 30c per share of common stock and operating partnership unit. The Prorated Dividend is payable on March 18 to common stockholders and operating partnership unitholders of record as of the close of business on March 15. The Prorated Dividend was declared by the board of directors in accordance with the Agreement and Plan of Merger, dated as of December 6, 2020, by and among Ready Capital, RC Merger Subsidiary, LLC and Anworth Mortgage Asset Corporation relating to the previously announced merger of Ready Capital and Anworth.

18:11 EST TTEC Holdings raises semi-annual dividend by 7.5% to 43c per share - The dividend is payable on April 21, 2021 to shareholders of record as of April 5, 2021.

17:59 EST SPDR Gold Shares holdings fall from 1,093.53MT to 1,084.50MT - This is the 7th consecutive decrease and the lowest level of holdings since May 12th, 2020.

17:26 EST Zoom Video jumps 8% to $444.10 after Q4 results, FY22 guidance beat estimates

17:17 EST Five9 VP Leena Mansharamani sells over $1.2M in shares - Five9 VP Leena Mansharamani disclosed in a filing that she had sold 6,547 shares of stock at $183.73 per share on February 25, for a total transaction amount of $1,202,880.

17:03 EST Macy's eliminates COO role, appoints Laura Miller as Chief Information Officer - Macy's announced changes to its senior leadership team. Aligned with the company's recently updated Polaris growth strategy, these changes to increase agility and efficiencies include: John Harper, COO, will depart the company effective August 1. Subsequently, the role of COO will be eliminated. With the elimination of the COO role, Marc Mastronardi, Chief Stores Officer, and Dennis Mullahy, Chief Supply Chain Officer, will report to CEO Jeff Gennette. Laura Miller has been appointed Chief Information Officer, effective March 15. Most recently, she served as Chief Information Officer of InterContinental Hotel Group (IHG). Miller succeeds Chief Technology Officer Naveen Krishna, who is leaving the company. Marla Beck, Bluemercury's CEO and co-founder, will leave the company this summer. Macy's has commenced a search for a new CEO. Chuck DiGiovanna, currently VP, real estate, has been appointed to lead Macy's real estate function, succeeding Douglas Sesler, who is leaving the company.

17:01 EST TriCo Bancshares raises quarterly dividend to 25c from 22c per share - The dividend is payable on March 26, 2021 to holders of record on March 12, 2021.

16:47 EST Adverum Biotechnologies provides update on ADVM-022 clinical development path - Adverum Biotechnologies announced that it has gained alignment with the FDA on the clinical development path for ADVM-022, an investigational single, in-office intravitreal, or IVT, injection gene therapy for the treatment of wet age-related macular degeneration, or AMD. "Having clarity from U.S. regulators on our pivotal plans for ADVM-022 is a significant step forward in accelerating our mission to transform the lives of millions of patients around the world living with wet AMD and at risk of losing their vision," said Laurent Fischer, M.D., chief executive officer at Adverum Biotechnologies. "Based on the results in our OPTIC trial to date and our discussion with the FDA, we can now initiate two global Phase 3 trials and have alignment on both clinical development and CMC requirements to support a BLA submission anticipated in 2024. Our team is well prepared to execute this new fast-to-market approach. In preparation of our potential commercialization of ADVM-022 targeting the treatment of millions of patients worldwide, we are expanding our CMC capabilities and investing in an in-house GMP manufacturing facility. Our goal is to deliver a one-time, in-office treatment that preserves patient sight for life."

16:43 EST Bottomline Technologies Bottomline appoints Bruce Bowden CFO - Bottomline announced that Bruce Bowden has joined the company as Chief Financial Officer. Following a previously-announced transition, Bowden will assume full responsibilities of the role on March 12. Bowden joins Bottomline from Interactions, a recognized leader in artificial intelligence and the development of intelligent virtual assistants that combine AI and human understanding to improve how businesses and consumers communicate. As its Chief Financial Officer, Bowden increased operational efficiency to accelerate growth and implemented multiple projects to improve top- and bottom-line performance. Previously, Bowden led corporate development, strategic planning and investor relations at Nuance Communications. As Chief Transformation Officer he was instrumental in accelerating both organic growth and earnings per share. "Bruce brings an outstanding record of accomplishment and results within high-growth technology companies," said Rob Eberle, CEO, Bottomline. "I am confident he will play an important role

16:36 EST SP Plus selected to provide parking management, shuttle operations at STL - SP Plus announced its selection to provide parking management and shuttle operations at St. Louis Lambert International Airport, or STL, in Missouri. SP+ took over the airport's parking operations on March 1 for more than 9,000 available spaces within two parking garages and five surface lots at STL.

16:35 EST Scientific Games drops 5% to $48.00 after reporting Q4 results

16:34 EST Nike head of North America, Ann Hebert, resigns - NIKE announced that Ann Hebert, Vice President and General Manager, North America geography, has departed from the company, effective today, March 1. Hebert leaves Nike after more than 25 years with the brand. Nike plans to announce a new head of its North American geography shortly.

16:32 EST Parsons awarded $2B ceiling Air Force Base modernization contract - Parsons was awarded an indefinite-delivery, indefinite-quantity multiple award task order contract by the U.S. Air Force Civil Engineer Center for architecture engineering capabilities, including design, construction management, and the restoration and modernization of Air Force Bases worldwide. The potential 10-year contract has a five-year base period and an option for an additional five years, worth a shared value of $2B across awardees.

16:31 EST Sherwin-Williams COO David Sewell resigns, effective March 12 - The Sherwin-Williams Company announced that David B. Sewell, President and COO, has notified the company of his decision to resign effective as of the close of business on March 12, to become CEO of another company outside of the coatings industry. Sewell's COO role will not be filled immediately. CEO Morikis will serve as President in addition to his current role and assume Sewell's primary duties and responsibilities.

16:30 EST Invitation Homes names new Chief Investment Officer - Invitation Homes announced the promotion of John Gibson to executive vice president and chief investment officer, effective immediately. Mr. Gibson joined Invitation Homes in December 2016 as senior vice president, Asset Management. He was promoted to Executive Vice President, Portfolio Management, in March 2019. Prior to joining Invitation Homes, Mr. Gibson spent 21 years with Goldman Sachs and its subsidiary, Archon Group, with various positions in real estate asset management, strategy, and people management, operating from both domestic and international bases.

16:20 EST Columbus McKinnon acquires Dorner Manufacturing for $485less than - Columbus McKinnon announced that the Company has executed a definitive agreement to acquire Dorner Manufacturing Corporation, an automation solutions company providing unique, patented technologies in the design, application, manufacturing and integration of high-precision conveying systems, from global private markets firm EQT. The cash transaction valued at $485M is expected to close early in the company's first quarter of fiscal 2022, subject to typical closing conditions and regulatory requirements.

16:17 EST Installed Building Products acquires I.W. International Insulation - Installed Building Products, announced the acquisition of I.W. International Insulation, Inc. doing business as Intermountain West Insulation. The company primarily provides insulation installation services to residential customers throughout Washington, Oregon, and Idaho. The acquisition adds approximately $34.4M of annual revenue.

16:14 EST Equity Commonwealth announces $150M share repurchase

16:13 EST Kroger announces retirement of EVP and COO Mike Donnelly - Kroger announced the retirement of Mike Donnelly, executive vice president and COO, after more than 42 years of distinguished service, effective later this spring. A succession plan will be announced at a later date.

16:08 EST Pool Corp. CFO Joslin to retire, Melanie Housey to succeed - Pool Corporation announced that Mark W. Joslin will retire as Senior Vice President, Chief Financial Officer, CFO and Treasurer in 2021 after more than sixteen years of service with the company. The Board of Directors has appointed Melanie Housey Hart to be the company's next CFO. Mrs. Hart currently serves as the company's Vice President, Corporate Controller and Chief Accounting Officer. Mr. Joslin will continue in his role until later this year in order to ensure a successful transition.

16:05 EST Alarm.com extends security technology to vehicles - The company states: "Alarm.com (ALRM) is connecting your car and home through its integrated security platform to help people stay informed about their vehicle's status and unlock more home automation capabilities. Alarm.com Connected Car, developed in collaboration with vehicle telematics solutions pioneer CalAmp (CAMP), offers all the benefits of a vehicle monitoring solution plus the unique benefit of deep integration with the Alarm.com smart home security system. Vehicle insights, notifications and home automation features are all accessible through one interface - the Alarm.com mobile app. Compatible with most cars manufactured since 1996, the Connected Car device plugs into a vehicle's OBD-II port for easy self-installation, reducing the need for costly truck rolls to add the device. Connected Car uses a dedicated cellular connection and has a battery backup, so it communicates with the home system and end user, even when the vehicle's engine is off."

16:01 EST John Bean Technologies acquires Acquires AutoCoding Systems for $17M - JBT announced it acquired AutoCoding Systems Ltd., a leading provider of software solutions for the automated set-up and control of end-of-line packaging devices. AutoCoding extends JBT's capabilities in packaging line equipment and associated devices, including coding and label inspection and verification. The company is headquartered near Runcorn, U.K., with additional operations in the U.S. and Australia, and generates approximately $7M in annual revenue. The purchase price was approximately $17M, before customary post-closing adjustments. After transaction-related costs and purchase price accounting associated with the acquisition, the transaction is expected to negatively impact GAAP earnings per share by approximately 1c-2c in 2021.

15:39 EST Danone board supports separation of Chairman and CEO roles - Danone's board of directors confirms unanimous support for Emmanuel Faber, who proposes the separation of Chairman and CEO roles. Following a meeting on March 1, Danone's board of directors reviewed the company's corporate governance and decided, on a proposal from Emmanuel Faber, to separate the functions of Chairman and CEO in the near future. The separation will be effective upon the appointment of a new CEO. The process to recruit a new CEO has been launched and once complete, Emmanuel Faber will focus on his role as non-executive Chairman. In the meantime, Emmanuel Faber will continue as Chairman and CEO, "with the full confidence and unanimous support of the Board to exercise full operational responsibility for the company, and to lead the implementation of the adaptation plan Local First," the company announced.

15:04 EST Hoth Therapeutics completes recruitment for Cohort 1 of BioLexa platform trial - Hoth Therapeutics announced it has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema. "We believe there continues to be an unmet need for improved topical therapy for those patients suffering from mild to moderate eczema," stated Robb Knie, CEO of Hoth Therapeutics, "We are pleased with how quickly Cohort 1 of Part A of our clinical trial has reached full recruitment and we are hopeful to announce preliminary results from this trial later in the year. We are continuing our mission to bring patient focused therapies to the clinic and improve quality of life across multiple indications."

14:54 EST Delek US says will review letter received from CVR, 'respond in due course' - Delek US Holdings (DK) issued the following statement regarding the Section 220 books and records request letter sent by CVR Energy (CVI), a majority owned subsidiary of Icahn Enterprises L.P. (IEP):" Delek will review the Section 220 books and records request letter that we received from CVR this morning. CVR has launched its activism campaign and proxy fight to drive its agenda - which we believe is not in the best interests of Delek shareholders. Indeed, CVR's previous letter demanded that Delek take a number of actions that would benefit CVR, to the detriment of Delek and its shareholders. The successful execution of Delek's long-term strategy has clearly delivered value for our shareholders, demonstrated by a five-year total shareholder return of +92% in comparison to +28% for the average of our peers, including CVR, over the same period. We will review and respond to CVR's letter in due course."

14:04 EST J.B. Hunt Chairman James Thompson sold over $750K in company shares - J.B. Hunt Chairman James Thompson disclosed in a filing, that he had sold 5,000 shares of company stock at $150.87 per share on March 1, for a total transaction amount of $754,355.

13:40 EST Lightning eMotors teases use of electric delivery vans by Amazon - Lightning eMotors sent out a tweet that reads "Package Status: Out for Delivery" with a photo of an Amazon (AMZN) Prime "100% electric" delivery truck in a possible teaser of a further announcement. As previously reported, Lightning eMotors and GigCapital3 (GIK), a special-purpose acquisition company or SPAC, announced that they have entered into a definitive agreement for a business combination. Upon closing of the business combination, the combined operating company will be named Lightning eMotors and will be listed on the New York Stock Exchange under the ticker symbol "ZEV." Reference Link

12:26 EST Sorrento, Scilex to acquire Aardvark Therapeutics' ARD-301 - Sorrento Therapeutics and Scilex Holdings Company, a majority owned subsidiary of Sorrento, have entered into an exclusive licensing term sheet with Aardvark Therapeutics to acquire Aardvark's proprietary formulation, Delayed Burst Release Low Dose Naltrexone, or ARD-301, for the treatment of chronic pain, fibromyalgia, and chronic post-COVID syndrome in multiple Phase 2 programs planned to be initiated this year. Following execution of the definitive agreement between the parties, Scilex plans to work with Aardvark to initiate a new Phase 2 trial this year for fibromyalgia, which Scilex believes will be an important milestone for treating physicians, and most importantly for the estimated 10 million U.S. adults suffering from this chronic, frequently debilitating central pain condition with limited treatment options. Approximately one-third of those diagnosed with fibromyalgia in the U.S. are reported to receive chronic prescription opioids, which is part of the opioid crisis, since opioids are not believed to be an effective solution for chronic central pain. ARD-301 is comprised of a non-opioid, non-addictive therapy option that has been shown to have activity for improving a broad array of fibromyalgia symptoms in prior clinical studies with LDN. Currently, there are only three FDA approved pharmacologic treatments for fibromyalgia, but they have demonstrated limited efficacy and burdensome side effects in many patients.

12:13 EST EDF Renewables signs virtual power ppurchase agreement with Enterprise Products - EDF Renewables North America announced a power purchase agreement for the second tranche of the Space City Solar Project with an affiliate of Enterprise Products Partners L.P. for 100 MWac / 132 MWdc. The Project's total capacity is up to 345 MWac / 455 MWdc. Space City Solar, located in Wharton County, Texas, is expected to commence construction in Summer 2021 and begin delivery of clean electricity in Summer 2022. Approximately 300 jobs are expected to be created during the construction phase with more than $30 million generated in new tax revenue over the operating life for Wharton County taxing entities.

12:00 EST Direxion Financial Bear 3x falls -7.4% - Direxion Financial Bear 3x is down -7.4%, or -39c to $4.86.

12:00 EST Civeo falls -9.3% - Civeo is down -9.3%, or -$1.75 to $17.04.

12:00 EST HCI Group rises 30.0% - HCI Group is up 30.0%, or $17.35 to $75.22.

11:54 EST Quidel receives EUA for QuickVue At-Home COVID-19 Test - Quidel Corporation announced that it has received an Emergency Use Authorization from the U.S. Food and Drug Administration, allowing the company to market its new QuickVue At-Home COVID-19 Test for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2. This test is authorized for prescription home use with self-collected anterior nares swab specimens directly from individuals aged 14 years and older who are suspected of COVID-19 by their healthcare provider within the first six days of the onset of symptoms. This test is also authorized for prescription home use with adult-collected anterior NS samples directly from individuals aged 8 years or older who are suspected of COVID-19 by their healthcare provider within the first six days of the onset of symptoms.

11:22 EST BurgerFi appoints Martha Stewart to board of directors - BurgerFi International has named Martha Stewart to its Board of Directors as Chair of the Product & Innovation Committee. Stewart is the Founder of the first-ever multi-channel lifestyle company, Martha Stewart Living Omnimedia, an entrepreneur, bestselling author of 98 to-date lifestyle and recipe books, and an Emmy award-winning and James Beard award-winning television show host.

11:05 EST Phillips 66 appoints Mark Lashier as president, COO - Phillips 66 has named Mark Lashier, President and CEO of Chevron Phillips Chemical Company, as its President and COO effective April 1. Lashier has served as CPChem's CEO since 2017. He joined the global petrochemical joint venture, in which Phillips 66 owns a 50% interest, in 2000.

10:46 EST Medtronic recalls HVAD Pump Implant Kit over delayed, failed restart - Medtronic is recalling the HVAD Pump Implant Kit because the device may fail to initially start, restart, or have a delay in restarting after the pump was stopped, the FDA announced. These delays or failures to start or restart have occurred during preimplant testing, during the implant, or in a variety of post-implant situations, it added. If the device has delays or fails to start or restart, this could cause serious patient harm including a heart attack, worsening heart failure, the need for additional procedures and hospitalizations, or death, the agency said. There have been 29 complaints about this device issue, which include 19 serious injuries and eight cases of patients who had a life-threatening event but recovered without long term effects. The FDA has identified this as a Class I recall, the most serious type of recall. Reference Link

10:30 EST FedEx begins shipping newly approved Covid vaccine on behalf of McKesson - FedEx Express, a subsidiary of FedEx Corp. (FDX), announced that it has begun shipping the newly approved COVID-19 vaccine on behalf of McKesson Corp. (MCK) to dosing centers throughout the United States. The company has shipped millions of COVID-19 vaccines since U.S. distribution began in mid-December 2020 and is prepared to scale up to accommodate anticipated growth in vaccine volume throughout the spring and summer. Nearly three months after COVID-19 vaccine distribution began, FedEx has shipped COVID-19 vaccines and supply kits to administration sites across all 50 states, Puerto Rico, the U.S. Virgin Islands, and Washington, D.C. COVID-19 vaccine volume is split evenly with FedEx moving approximately half the doses allocated by the federal government. "As vaccine production ramps up and more vaccines are approved, we expect to see a significant uptick in COVID-19 vaccine and supply kit volume moving through our network," said Don Colleran, president and CEO for FedEx Express. "As manufacturers obtain approval to ship COVID-19 vaccines with greater temperature ranges and varying dosing allotments, we anticipate more of these packages moving to more places through our global network."

10:16 EST Workhorse Group has scheduled a face-to-face meeting with USPS on March 3 - Comments taken from Q4 earnings conference call.

10:05 EST Epam Systems to acquire PolSource, terms not disclosed - EPAM Systems (EPAMO announced its agreement to acquire PolSource to scale EPAM's growing Salesforce (CRM) capabilities and expansion into new markets. The proposed acquisition is expected to close at the beginning of EPAM's fiscal second quarter, subject to required regulatory approvals and other customary closing conditions, at which time PolSource's senior leadership team and hundreds of Salesforce experts will join forces with EPAM Systems. PolSource is known as a global boutique Salesforce partner, specializing in consultancy services and delivering powerful digital transformation solutions.

10:01 EST Pros Holdings names Katrina Klier Chief Marketing Officer - Pros Holdings (PROS) announced that Katrina Klier has joined the company as Chief Marketing Officer. Klier will be responsible for "aligning global marketing strategy and programs with corporate priorities." Prior to Pros, Klier served as global managing director and head of digital marketing, communications and capabilities at Accenture (ACN).

10:00 EST Direxion Financial Bear 3x falls -6.5% - Direxion Financial Bear 3x is down -6.5%, or -34c to $4.91.

10:00 EST Small Cap Bear 3x falls -7.9% - Small Cap Bear 3x is down -7.9%, or -37c to $4.31.

10:00 EST HCI Group rises 36.3% - HCI Group is up 36.3%, or $21.00 to $78.86.

09:52 EST Morphic Holding Inc trading resumes

09:50 EST Boingo Wireless trading resumes

09:47 EST China Yuchai falls -6.5% - China Yuchai is down -6.5%, or -$1.03 to $14.71.

09:47 EST Fisker falls -9.3% - Fisker is down -9.3%, or -$2.66 to $25.84.

09:47 EST NRG Energy rises 16.8% - NRG Energy is up 16.8%, or $6.14 to $42.65.

09:36 EST Iteris board unanimously rejects unsolicited proposal from Rekor Systems - Iteris (ITI) announced that its Board of Directors has reviewed and unanimously rejected the non-binding, unsolicited proposal disclosed today by Rekor Systems (REKR) to acquire Iteris for consideration consisting of approximately 17% cash and 83% Rekor shares at current stock prices. "After a careful and thorough review, conducted in consultation with our independent advisors, the Iteris Board unanimously concluded that the unsolicited proposal significantly undervalues the Company and is not in the best interests of our shareholders," said Tom Thomas, Chairman of the Board of Iteris. "The Board is always looking for ways to maximize value for our shareholders, but Rekor's proposal does not reflect Iteris' intrinsic value, including the significant long-term opportunities ahead of us."

09:30 EST EnWave signs tech evalution, license option agreement with Sutas - EnWave Corporation announced today that it has signed a technology evaluation and license option agreement with Suta sut undefinedrunleriI. Suta will evaluate EnWave's proprietary Radiant Energy Vacuum dehydration technology for the dehydration of premium dairy snacks and ingredients. EnWave will install a 10kW REV machine at a site of Suta' choosing in Turkey for a period of up to six months for research and development purposes. The TELOA grants Suta the option to enter into a royalty-bearing commercial license to produce REV-dried commercial dairy products for both domestic and international sales. REV technology is currently being used commercially by more than a dozen dairy companies internationally. As part of the business transformation plan recently announced at NutraDried, Mr. Dan Henriques, EnWave's CFO, has been appointed as Chief Operating Officer of NutraDried to oversee the streamlining of operations. In recognition of this appointment, the Company has granted Mr. Henriques an aggregate of 142,000 incentive stock options, subject to the terms of the Company's Stock Option Plan , that are exercisable at the last closing price of the Company's common shares on the TSX Venture Exchange on February 26, 2021. The incentive stock options are exercisable for a term of five years expiring on February 26, 2026 and will vest in accordance to the provisions set out in the Plan, or as otherwise required by the TSXV. The Company also granted Mr. Henriques an aggregate of 25,000 Restricted Share Rights pursuant to the Company's Restricted Share Rights Plan. The RSRs granted will vest three years from the date of the award.

09:27 EST IMAC completes first cohort of Phase 1 study of mesenchymal stem cells - IMAC Holdings announces it has completed the first cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson's disease. The first cohort consists of five patients with bradykinesia due to Parkinson's disease receiving a low dose, intravenous infusion of the stem cell treatment. The cohort was completed on Friday, February 26, 2021. In accordance with the trial protocol, the Company will wait at least 30 days to demonstrate safety of the low dose before initiating the second cohort in which five patients will receive a medium intravenous dose.

09:22 EST Advent Technologies in pact with DOE 'for next-generation' fuel cell technology - Advent Technologies announced that it has signed a joint development agreement with the US Department of Energy'sLos Alamos National Laboratory Brookhaven National Laboratory and the National Renewable Energy Laboratory. Under this CRADA, along with support from the DOE's Hydrogen and Fuel Cell Technologies Office, Advent's team of scientists will work closely with its LANL, BNL, and NREL counterparts over the coming years in order to develop breakthrough materials that will help strengthen US manufacturing in the fuel cells sector and bring high-temperature proton exchange membrane fuel cells to the market. This project will also contribute to the acceleration of energy and transportation technologies that will enable a clean, zero-emissions energy future. The aim of HT-PEM fuel cells is to fulfill the promise of "Any Fuel. Anywhere." They can allow ships to run on renewable methanol or ammonia, airplanes to run on dimethyl ether or hydrogen, and off-grid power generators to work with any green fuel that is easily transportable to remote locations. The ability to use any hydrogen-carrying fuel, in addition to pure hydrogen, is a major breakthrough in reducing the required infrastructure investments. Dr. Emory De Castro, Advent's Chief Technology Officer, commented: "The developing world is where the battle of climate change will be won or lost, and a low-cost infrastructure is a must. Synthetic eFuels will be produced by green hydrogen in the near future and thus be sustainable in such applications. HT-PEM technology allows for hydrogen fuel flexibility, while the competition is currently limited to very pure hydrogen that is compressed at 700bar. By forging this partnership, we are taking yet another step closer to realizing our clean energy future."

09:21 EST Revival Gold announces results of gold mineralization at Beartrack-Arnett - Revival Gold is pleased to announce the results of a new appraisal of drill results and the recognition of a high-grade core of gold mineralization that is being evaluated for its underground potential at the past-producing Beartrack-Arnett Gold Project located in Idaho, USA. The appraisal was initiated earlier this year in response to Revival Gold's 2020 drilling results, the relogging of previously drilled core and fresh geological insights developed by the Company's exploration team led by Vice President Exploration, Steve Priesmeyer, with input from consulting geoscientists, Mira Geosciences Ltd., and Technical Advisors, 2021 Bill Dennis Award Winner, Phil Walford and noted international explorationist, Laurie Curtis. Key findings are as follows: Based on wide-spaced drilling, there appears to be a core of consistent high-grade sulphide gold mineralization that extends over one kilometer from the south end of the South Pit area through to the south end of the Joss area. The high-grade mineralization is situated within the near-vertical Panther Creek Shear Zone. Intersections run from 4 - 9 g/t gold and are estimated to range between 1 - 5 meters in true width. Mineralization at Joss has been tested over 300 meters vertically and extends to approximately 500 meters below the surface where it remains open at depth. The core is enveloped within a larger lower-grade halo of gold mineralization, some of which has been previously analyzed and included in the bulk underground mineable component of the 2020 Mineral Resource at Beartrack-Arnett. Cross structures are thought to be important controls on mineralization at Beartrack and such structures are evident at Joss. Intersection points with the PCSZ represent important drill targets. The zone is open to the south. To the north, the mineralization continues into the South Pit area, which hosts additional open pit and bulk underground mineable Mineral Resources.

09:19 EST Nevada Copper provides update on project development objectives - Nevada Copper is pleased to provide an update on its development objectives for its Pumpkin Hollow project. The Company's updated development objectives reflect internal studies regarding project optimization and expansion options, as well as the evolution of the copper market. These development objectives aim to further demonstrate the potential of Nevada Copper's large strategic land holding and organic pipeline. HIGHLIGHTS OF THE DEVELOPMENT OBJECTIVES: Prioritized development objectives to advance Nevada Copper's three key growth opportunities: Optimization and expansion of the fully permitted Open Pit Project; Exploration of the Company's multiple near-mine targets; Expansion and extension of the producing underground mine. Open Pit Advancement: Internal studies indicate optimized project scaling has potential to significantly improve project economics, including a concurrent phase 1 and phase 2, plus potential larger ultimate production scale; Infill and extension drilling with aim to bring newly defined mineral inventory into reserves - Conversion of known inferred resources also has potential to further improve project economics; The Company expects to release a resource and reserve update following drilling. Property Exploration: Property has been further expanded to the east, adding multiple targets; Geophysical surveys have identified multiple new targets; Drilling plans defined to follow-up on high-potential targets. Underground Future Extension: Inferred conversion: Significant additional inferred resources to be in-filled as underground mining advances into new zones. Exploration: Multiple underground mine extension targets to be further evaluated, including a new potentially large target to the east of the main shaft that is previously untested. Expansion: Future expansion potential to be studied post achievement of steady-state production.

09:18 EST Camac nominates seven candidates for election to Cedar Realty Trust board - Camac Partner announced that its affiliate has nominated a slate of seven highly qualified director candidates for election to the board of directors of Cedar Realty Trust. Camac is one of Cedar Realty's largest shareholders. Camac's nominees-Larry E. Jennings, Jr., Daniel Katz, Richard Ross, Eric Shahinian, Sharon Stern, Eric Ray and Archer Greg Stevenson-would each bring a welcome fresh perspective to Cedar Realty's board. These nominees are committed to acting in the best interest of all of Cedar Realty's shareholders as independent directors. Camac has received significant positive feedback since the release of its plan to unlock value at Cedar Realty. This feedback validates Camac's views that meaningful and immediate change is needed at Cedar Realty. Camac's plan is simple: Significant Board refreshment with highly qualified directors; Cost-conscious reorganization of Cedar Realty; Sale of non-core assets and deleveraging; Immediate halt to all value-destructive development projects; Implementation of a capital allocation strategy centered on return on invested capital; Appropriate, through and fair evaluation of value-maximizing transactions. Camac believes that Cedar Realty's board has failed to pursue or seriously evaluate credible inbound transaction inquiries. Camac believes that Cedar Realty's board has the fiduciary obligation to give shareholders-the true owners of Cedar Realty-the opportunity to consider and vote on potential value-maximizing transactions.

09:15 EST Boingo Wireless to become privately held company after Digital Colony buy

09:14 EST CDK Global completes International Business sale - CDK Global announced it has completed the previously announced sale of the CDK International business to Francisco Partners. CDK announced the agreement to sell the International Business on November 30, 2020. The sale was completed after meeting customary closing conditions and regulatory approvals. Further details regarding the transaction can be found on the Current Reports on Form 8-K filed with the Securities and Exchange Commission on November 30, 2020 and March 1, 2021.

09:10 EST Cyclo Therapeutics announces appointment of Gerald Cox as acting CMO - Cyclo Therapeutics announced the appointment of Gerald Cox as acting chief medical officer, or CMO. Cox is the founder of Gerald Cox Rare Care Consulting, where since 2018 he has been providing advice to small companies in all phases of clinical development for investigational rare disease drugs.

09:07 EST Nordstrom, Tonal form partnership - Tonal announced that it partnered with Nordstrom to bring its revolutionary intelligent strength training system to new customers across the country. Beginning in March, the experience will launch in the Women's Active department in 40 Nordstrom locations across 20 states in the U.S., including 12 states where Tonal had not yet had a physical location. The partnership will be brought to life through a 50 square foot concept where visitors can experience a full Tonal demo and try a workout firsthand. Store rollouts will begin in March, including top Nordstrom flagship stores in Seattle, Los Angeles, San Francisco, Chicago and Dallas.

09:05 EST Duck Creek Technologies appoints Courtney Townsend as CPO - Duck Creek Technologies announced that Courtney Townsend has joined the company as Chief People Officer. Townsend will be responsible for developing and executing Duck Creek's overall human resources strategy and plan, including culture development, inclusion and diversity, succession planning, talent management, change management, and organizational and performance management. She will report directly to CEO Michael Jackowski and work closely with the company's Executive Committee. Most recently, she served as Chief Human Resources Officer at Stats Perform, a sports technology company.

09:04 EST INVO Bioscience obtains regulatory approval to import INVOcell into Mexico - INVO Bioscience announced the company has received approval by COFEPRIS to import INVOcell into Mexico. In late 2020, INVO Bioscience established a joint venture focused on establishing fertility centers dedicated to offering INVOcell, with the initial center, called Positib Fertility, to be located in the city of Monterrey, Mexico.

09:03 EST MingZhu Logistics announces cooperation agreement with China Merchants - MingZhu Logistics Holdings announced a major cooperation agreement with Sinotrans Logistics Limited's wholly owned subsidiary, China Merchants Logistics Group Urumqi Limited. The cooperation agreement is designed to provide an exclusive, crucial link between the first and last mile between slack coal mines and essential railroads. Under the cooperation agreement, MingZhu will be responsible for the logistics and timely container transport of slack coal linking mines with essential railroad transportation. The companies expect the higher efficiency, lower cost intermodal transport services model will set a new standard for future transport. The cooperation agreement will initially focus on serving Xinjiang's fast growing slack coal market, with total market volume expected to grow from 72.3 million tons in 2018 to 87.7 million tons by the end of 2021. Xinjiang occupies a preeminent position as one of the core transportation hubs of the One Belt One Road and serves as a strategic gateway.

09:00 EST Boingo Wireless trading halted, news dissemination

08:56 EST MTBC announces name change to CareCloud - MTBC announced it is renaming the company to CareCloud, Inc. effective March 29, 2021. The name change reflects the company's continued commitment to bringing disciplined innovation and cloud-based solutions to today's evolving healthcare market. As a result of the company's consistent growth, strategic acquisitions and history of innovation over two decades, MTBC's solutions and market presence have expanded significantly, today powering more than 40,000 healthcare providers across 50 states, supported by more than 3,000 team members worldwide. Under the new CareCloud name, MTBC's common stock will continue to trade on the Nasdaq Global Market under the ticker symbol "MTBC", and its Series A Preferred Stock will also continue to trade under the ticker symbol "MTBCP".

08:55 EST Conduent announces partnership with Congruity360 - Conduent Incorporated announced a new agreement with Congruity360 that will bring advanced functionality to Conduent's Viewpoint eDiscovery software platform. With the integration of Congruity's Hold360 technology into Viewpoint, corporate legal teams now have a unique, all-in-one solution to streamline the eDiscovery process and smoothly transition from identification and preservation to review and production of legal matters.

08:55 EST Midwest Energy Emissions secures supply business fvalued at $2M+ annually - Midwest Energy Emissions announced that the Company has secured multi-year supply business with a large utility located in the Southwest region of the U.S. to provide its patented two-part Sorbent Enhancement Additive technology for mercury emissions capture. The new supply business for the Company was achieved through a competitive bid process and has a minimum expected value of $2 million per year.

08:52 EST Fluidigm granted EUA for kit for Advanta Dx SARS-CoV-2 RT-PCR Assay - Fluidigm Corporation announced that the U.S. Food and Drug Administration has granted Emergency Use Authorization for the AZOVA COVID-19 Test Collection Kit for use with the Fluidigm Advanta Dx SARS-CoV-2 RT-PCR Assay on the company's Biomark HD platform. The kit is authorized for at-home self-collection by prescription only for individuals suspected of COVID-19 by their health care providers. Those under the age of 18 may use the kit with adult supervision.

08:49 EST GTEC Holdings repays convertible debt in full - GTEC Holdings, is pleased to announce that it has repaid its Unsecured Convertible Promissory Note with Invictus MD Strategies Corp. in full. The Note, which was amended on October 30, 2020 had a principal balance of approximately $2 million, which carried an annual interest rate of 10%. During the most recent 30-day period, the Company made a series of payments, which fully repaid the principal balance of the loan and all accrued interest. The Company would like to reiterate its dedication to operate in a fiscally disciplined manner while building long-term shareholder value. The Company will continue evaluating opportunities to eliminate or reduce its debt, and to reduce operational expenses, while striving to increase its revenue and gross margins.

08:47 EST Michael Angelakis and Jeffrey Ubben join ExxonMobil board - Angelakis is chairman and CEO of Atairos, an independent strategic investment company focused on supporting growth-oriented businesses across a range of industries. Prior to founding Atairos, he served as Comcast Corporation's vice chairman and chief financial officer. In those roles, Angelakis led strategic planning, capital allocation and corporate development, including overseeing Comcast's successful transition into media and other technologies. Angelakis is a non-executive director of TriNet Group, Inc. and Groupon, Inc., and is a former chairman of the Federal Reserve Bank of Philadelphia. Ubben co-founded Inclusive Capital Partners, a San Francisco-based investment firm focused on increasing shareholder value and promoting sound environmental, social and governance practices. Previously, he was a co-founder of ValueAct Capital Partners, an investment firm emphasizing strong, constructive relationships with company management teams and boards. He is currently a non-executive director for Appharvest Inc., Enviva Partners LP and Nikola Corporation. "We welcome these new directors as part of our ongoing board refreshment, which builds on the diverse global business experience of our current members," said Darren Woods, chairman and chief executive officer of Exxon Mobil Corporation. "Michael and Jeff's expertise in capital allocation and strategy development has helped companies navigate complex transitions for the benefit of shareholders and broader stakeholders. Their contributions will be valued as ExxonMobil advances plans to increase shareholder value by responsibly providing needed energy while playing a leadership role in the energy transition."

08:44 EST Aemetis announces five-yeatr plan targeting $1B of revenue by 2025 - Aemetis has rolled out a new five-year plan that positions the company to generate $1.07 billion of revenues and $325 million of adjusted EBITDA in year 2025. The Revenues plan is a CAGR of 35% and the EBITDA growth plan is a CAGR of 109% for the years 2021 to 2025. The Aemetis five-year plan is being presented today during the 2021 Credit Suisse Virtual Energy Conference, including a one hour presentation on Tuesday, March 2 at 4 pm Eastern time by Eric McAfee, the Chairman and CEO of Aemetis. The presentation also will be filed today with the SEC under Form S-8. The conference presentation by Mr. McAfee will include a question and answer session with two Credit Suisse renewable energy stock analysts focused on negative carbon intensity Renewable Natural Gas, renewable jet/diesel fuel produced using cellulosic negative carbon intensity hydrogen, and other below-zero-carbon projects that Aemetis is building to maximize the value of the California Low Carbon Fuel Standard and federal Renewable Fuel Standard. The majority of the Company's revenue growth is expected to come from California dairy Renewable Natural Gas and the Aemetis "Carbon Zero" renewable jet/diesel plants using negative carbon intensity cellulosic hydrogen produced from waste almond orchard wood in Central California. The Aemetis Dairy RNG project plan shows revenues growing from $9 million in 2021 to $175 million in 2025, while Dairy RNG project EBITDA expands from $4 million in 2021 to $141 million in 2025. Aemetis has been awarded $23 million of grants related to dairy RNG and related gas cleanup and utility pipeline interconnection units, including a $1 million grant to install an RNG dispensing station to fuel RNG trucks at the Keyes plant. The Aemetis "Carbon Zero" renewable jet/diesel plants utilizing estimated -80 negative carbon intensity cellulosic hydrogen are planned to grow to $467 million revenues and EBITDA of $136 million in year 2025.

08:43 EST NYSE to delist Cnooc American depositary shares - In a regulatory filing, Cnooc announced The New York Stock Exchange posted on its website stating that the NYSE Regulation has determined to commence proceedings to delist the American depositary shares of the company on the basis that the company is no longer suitable for listing pursuant to NYSE Listed Company Manual Section 802.01D in light of the executive order signed by the President on November 12 2020 and updated guidance provided by the Office of Foreign Assets Control of the US Treasury Department in General License 1A and frequently asked questions 879 issued on 27 January 2021. The NYSE will suspend trading in the ADSs on March 9. The NYSE will apply to the US Securities and Exchange Commission to delist the ADSs upon completion of all applicable procedures, including any appeal against the NYSE Regulation's decision.

08:42 EST Lottery.com appoints Luc Vanhal as CFO - Lottery.com announced that Luc Vanhal has been appointed as the Company's CFO. Since 1990, Vanhal has been providing executive leadership in the roles of chief financial officer, chief operating officer and president. As CFO, Vanhal will lead Lottery.com's global finance organization and will be responsible for accounting, treasury, financial planning and analysis. He will also play a crucial role in Lottery.com's global expansion plans, in both regulatory matters and acquisitions. On February 22, 2021, the Company entered into a definitive agreement with Trident Acquisitions Corp. to become a publicly traded company on The Nasdaq Stock Market. Trident and the Company intend to publish an investor presentation relating to the proposed business combination in the coming weeks.

08:40 EST Newtek Business Services reaches $500M in market capitalization - Newtek Business Services announced that it has reached $500 million in market capitalization, based on the closing price of Newtek's common stock of $22.98 per share on Friday, February 26, 2021. Barry Sloane, President, Chairman and CEO commented, "We are extremely proud to have reached this milestone, which underscores the strength of our business model and its ability to adapt to and excel in a rapidly changing environment as we continue to assist independent business owners with their needs across the U.S. in all 50 states. In addition, we believe reaching a $500 million market capitalization could open us to greater acceptance by small-cap investors with an investment thesis that requires a minimum market capitalization threshold of $500 million We look forward to our next milestone of reaching $1.0 billion in total assets."

08:39 EST Greenland Technologies plans major U.S. manufacturing expansion - Greenland Technologies Holding Corporation announced a planned major U.S. manufacturing expansion that will establish Greenland's U.S. market manufacturing footprint and increase its total worldwide capacity. Under the planned expansion, Greenland is in discussions to establish a new up to 50,000 square foot facility on the East Coast of the U.S. Depending on the favorable outcome of discussions regarding potential incentive programs with state and local officials, Greenland plans to finalize the site selection process and formally announce the state the new facility will be located in during 2Q 2021. The company is targeting 3Q 2021 to take possession of the additional manufacturing space, with assembly lines brought fully online for its upcoming electric industrial vehicles targeted between 3Q 2021 and 4Q 2021.

08:36 EST Sabre, Kiwi.com announce new strategic partnership - Kiwi.com and Sabre announced a new strategic partnership. The agreement will see Kiwi.com leverage Sabre's well-established global position to support its continued growth and expand its market reach.

08:35 EST Qualigen Therapeutics secures option to negotiate license for AS1411-GNP - Qualigen Therapeutics announced it has entered into a Material Evaluation and Option Agreement with the University College London to advance development of and potentially expand toward future commercial uses of Qualigen's leading anticancer drug candidate AS1411-GNP, also known as ALAN. In collaboration with the University of Louisville, Qualigen will evaluate the use of ALAN with G-quadruplex binders developed by Professor Stephen Neidle and colleagues from UCL. Research at UCL, supported by the UCL Technology Fund, has shown encouraging results using GQBs and targeted cancer therapeutics, particularly for the treatment of pancreatic cancer. Qualigen believes the combination of these GQBs with ALAN may increase the cancer selectivity, and therefore also the efficacy, of ALAN. Qualigen has secured an option to pursue a worldwide commercial license for this promising technology from UCL Business Ltd, the commercialization company of UCL. ALAN is a combination of Qualigen's AS1411 DNA aptamer plus a DNA-coated gold nanoparticle to dramatically increase its potency. This cancer drug candidate has the potential to target and destroy tumor cells in a various types of cancer with minimal side effects. The Company is aiming to commence Phase 1 human trials in 2021 for acute myeloid leukemia, its lead indication. Qualigen has an exclusive worldwide license agreement from the University of Louisville for ALAN.

08:34 EST Lantheus announces publication of PyL results from pivotal studies - Lantheus Holdings announced the publication of the results of both pivotal studies for PyL, an investigational PET imaging agent that targets prostate-specific membrane antigen. The OSPREY Phase 2/3 trial results have been published online in the Journal of Urology and the CONDOR Phase 3 trial results have been published in the online version of Clinical Cancer Research. "The limitations of conventional imaging modalities for prostate cancer create a need for targeted imaging in the initial assessment of high-risk patients as well as in men with early biochemically relapsed disease," said Michael J. Morris, M.D., Prostate Cancer Section Head, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, and lead author of the CONDOR manuscript and senior author on the OSPREY manuscript. "The OSPREY trial data highlighted the high positive predictive value, negative predictive value and specificity of PyL in staging high-risk patients. The CONDOR trial demonstrates its high positive predictive value to accurately locate and identify recurrent cancer early and non-invasively. Assuming FDA approval, physicians will be able to use this clinically meaningful information to identify disease, guide treatment plans, and improve disease management."

08:33 EST Atlantica Sustainable Infrastructure to acquire Coso Geothermal Power Holdings - Atlantica Sustainable Infrastructure announced that it has reached an agreement to acquire Coso Geothermal Power Holdings, a 135 MW geothermal power plant, from a consortium of investors including Bardin Hill Investment Partners LP, Avenue Capital LP, Corre Partners Management, LLC and Voya Financial. As the third largest geothermal power plant in the United States, Coso plays a critical role in supporting California's decarbonization efforts. Atlantica's investment is expected to be approximately US $170 million and to close in the first half of 2021, subject to customary conditions and regulatory approvals. The asset provides base-load, non-intermittent, renewable energy to the California ISO and has PPAs signed with three investment grade offtakers, with 19 years average contract length. Following the close of the transaction, Coso's existing management team and the asset management team at Middle River Power will continue to lead the plant's operations.

08:32 EST Chinook Therapeutics, Evotec enter collaboration for chronic kidney diseases - Chinook Therapeutics (KDNY) and Evotec (EVTCY) announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases. Based on Evotec's proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterize and validate novel mechanisms and discover precision medicines for PKD, lupus nephritis, IgA nephropathy and other primary glomerular diseases. The collaboration will also involve further characterization of pathways and patient stratification strategies for programs currently in Chinook's clinical and preclinical pipeline. The National Unified Renal Translational Research Enterprise is the first biobank for chronic kidney diseases and nephrotic syndrome, covering England, Scotland and Wales. Biological samples, including plasma, serum, urine, DNA and kidney biopsies, from 3,000 patients with chronic kidney diseases and over 800 patients with NS from 18 NHS Trusts, are being collected and stored under strict standards for academic and industrial research globally. NURTuRE also has the advantage of containing anonymized linked clinical data through the U.K. Renal Registry, which will enable the development of new prognostic and predictive biomarkers. This will potentially allow Chinook and Evotec to identify patients who will benefit from better, earlier diagnosis and individualized new treatments, resulting in improved health outcomes. The collaboration also leverages Evotec's proprietary PanOmics platform, which combines enhanced throughput proteomics, high throughput transcriptomics and cell imaging with PanHunter, Evotec's unique data analysis platform. Under the terms of the agreement, Chinook and Evotec will share drug discovery and preclinical development responsibilities. Chinook will be responsible for clinical development and commercialization of product candidates developed under the collaboration. Evotec will receive an undisclosed upfront payment, research funding, progress-dependent milestone payments and tiered royalties on net sales for targets identified through the collaboration.

08:29 EST FluroTech appoints Phillip Farrelly to Scientific Advisory Board - FluroTech announced that Phil Farrelly has joined FluroTech's advisory board. Mr. Farrelly founded Hudson Robotics in 1983, establishing the company as a market leader in microplate automation, laboratory robotics, liquid handling and customized software-driven laboratory automation solutions for life sciences research.

08:26 EST Cummins announces Nicole Lamb-Hale to be be General Counsel - Cummins announced Nicole Y. Lamb-Hale is succeeding Sharon Barner as Vice President and General Counsel, effective in May. The company announced on February 2 that Barner is being promoted to Vice President and Chief Administrative Officer.

08:25 EST R1 RCM issues inaugural ESG report - R1 RCM released its inaugural Environmental, Social, and Governance Report detailing R1's approach to ESG, corporate responsibility, and sustainability. As a trusted partner to its customers, and the patients and communities they serve, R1 built an ESG framework that aligns with the United Nations Sustainable Development Goals and demonstrates a commitment to transparency, accountability, and social responsibility to its stakeholders.

08:24 EST ManTech appoints Joseph Cubba as CGO - ManTech (MANT) announced the appointment of Joseph Cubba as Chief Growth Officer. Reporting to COO Matt Tait, Cubba will plan and lead strategic growth priorities for sales, revenue and profit, leveraging ManTech's innovative technology solutions and outstanding talent to build on the company's strong customer relationships in intelligence, defense and federal civilian agencies. Cubba joins ManTech from IBM (IBM), where he served most recently as Senior Partner and Vice President, Defense and Intelligence, driving growth in AI, machine learning, advanced analytics, hybrid cloud and next generation enterprise IT, winning the Federal 100 Award for his achievements.

08:21 EST Accenture to acquire Pollux, terms undisclosed - Accenture has agreed to acquire Pollux, a provider of industrial robotics and automation solutions, headquartered in Joinville, Brazil. The company said the acquisition will expand Accenture's capabilities for clients in consumer goods, pharmaceutical and automotive industries seeking to make their factories, plants and supply chains more productive, safe and sustainable. Pollux provides solutions to optimize manufacturing and logistics processes. The company designs, engineers and deploys functional assembly lines that include robots and other hardware, plus the software that controls them. Pollux also offers visual analytics inspection solutions, autonomous mobile robots and robots as a service for shopfloors and warehouses. Founded in 1996, Pollux has implemented more than 1,000 projects for manufacturing companies, primarily in Brazil.

08:21 EST China Biologic announces shareholders' approval of merger agreement - China Biologic announced that, at an extraordinary general meeting, the company's shareholders voted in favor of the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of November 19, 2020, among the company, CBPO Holdings Limited and CBPO Group Limited, pursuant to which, Merger Sub will be merged with and into the company with the company continuing as the surviving company and becoming a wholly owned subsidiary of Parent, the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands, and the transactions contemplated thereby, including the Merger.

08:20 EST Camping World to acquire Triple A R.V. Center in Oregon - Camping World announced that an agreement has been signed to acquire Triple A R.V. Center in Medford, Oregon. The acquisition is anticipated to close this month. The location will transition to the Camping World brand with a target open date of late March. The SuperCenter will include a wide range of new and used RVs from manufacturers in addition to a full assortment of RV and outdoor products and accessories. With this addition, the company will have six locations in Oregon. Camping World Holdings also owns and operates a second location south of Medford under its Gander RV & Outdoors brand, America's second largest RV and outdoor dealer network behind Camping World.

08:18 EST TransAct Technologies gets BOHA! agreement with regional convenience store - TransAct Technologies announced that it has secured a new BOHA! agreement with a regional convenience store operator. The company expects to deploy the BOHA! system to over 40 locations in support of their privately-branded and third party fresh food offerings. "TransAct's BOHA! Solutions have rapidly become an industry leader for c-store operators as they continue to expand into freshly prepared & pre-packaged foods," said Bart C. Shuldman, Chairman and CEO of TransAct Technologies. "We are thrilled to have another customer recognize the immense power of the BOHA! platform, and look forward to working and growing with them." The complete system deployment will initially include the BOHA! Terminal, BOHA! Labeling Software, and proprietary BOHA! labels. TransAct estimates total annual recurring revenue per unit will be at least $1,500 per year, with one-time hardware revenue sales of at least $900 per location.

08:16 EST Atlantica Sustainable Infrastructure sees mid-term CAFD per share growth 5%-8% - Considering these opportunities, Atlantica has targeted mid-term CAFD per share growth of between 5% and 8%.

08:16 EST Atlantica Sustainable Infrastructure provides guidance for growth beyond 2021 - The Company believes that its accretive growth strategy is supported by significant potential equity investment opportunities identified in the short and mid-term in the regions and sectors where it has a presence. Given the pipeline of opportunities, Atlantica targets potential equity growth investments of approximately $300 million per annum in equity value. Atlantica has diversified sources of growth: Organic growth can be delivered through the optimization of the existing portfolio, escalation factors in many of our assets and the expansion of current assets, particularly our transmission lines. Additionally, we expect to find opportunities to expand or repower some of our renewable assets. Development of new assets. The Company intends to invest and co-invest in developing assets with partners, including AAGES, and in some cases internally. Third-party acquisitions. In addition, Atlantica expects to continue acquiring assets from third parties, leveraging its local presence and network in different geographies and sectors.

08:15 EST Atlantica Sustainable Infrastructure sees 2021 CAFD $220M-$240M - With this, Atlantica is initiating guidance for 2021: 2021 targeted Adjusted EBITDA including unconsolidated affiliates in the range of $820 million to $860 million. 2021 targeted CAFD in the range of $220 million to $240 million, an equivalent of $1.99 to $2.17 per share.

08:13 EST Phio Pharmaceuticals, AgonOx announce clinical development collaboration - Phio Pharmaceuticals announced it has entered into a clinical development collaboration with AgonOx to develop novel T cell-based cancer immunotherapies using Phio's lead INTASYL based product candidate PH-762 and AgonOx's "double positive" tumor-infiltrating lymphocyte technology. The companies have shown that the combination of their respective technologies can result in enhanced TIL therapeutics, and based on these data, the collaboration will focus on conducting a clinical study for PH-762 treated DP TILs. The study is expected to start enrolling patients later this year.

08:12 EST Hershey announces 2030 goals to reduce environmental footprint - The Hershey Company announced new commitments to advance its environmental progress and contribute to global climate action. Hershey has set ambitious new goals to reduce its global emissions in line with the global best practice of the Paris Climate Agreement, to limit global temperature rise to 1.5 degrees C. In 2019, Hershey committed to the Science Based Targets initiative that it would audit its operations and develop targets to reduce its greenhouse gas emissions in line with the best available climate science. As a result of that process, Hershey announces its goal to reduce its absolute Scope 1 and Scope 2 emissions by more than 50% and its absolute Scope 3 emissions by 25% by 2030, compared to a 2018 baseline. Hershey will deploy a comprehensive, global approach to reduce emissions through targeted investments in energy efficiency, renewable energy, packaging innovations as well as sustainable land-use policies.

08:11 EST SIC appoints Karl Adrian president, residential design services - Select Interior Concepts announced that Karl Adrian will join the Company as President, Residential Design Services effective March 1, 2021. Most recently, he served as CEO of Clio Holdings, a large fabricator of stone and other countertops with multiple manufacturing facilities and other locations.

08:09 EST Amyris to acquire Costa Brazil brand, terms not disclosed - Amyris announces that it has entered into an agreement to acquire Costa Brazil. Amyris is accelerating its growth and market leadership in clean beauty with the addition of Costa Brazil to its family of consumer brands, including Biossance, Pipette, Rose Inc., JVN, and Terasana. With the acquisition of Costa Brazil, Amyris will appoint Francisco Costa as Chief Creative Officer of the company. A definitive agreement is expected to be signed by the end of March and, subject to customary closing conditions, the transaction is expected to close at that same time.

08:08 EST Twilio to invest up to $750M in Syniverse to become significant minority owner - Syniverse and Twilio announced that they have entered into a partnership to accelerate the next wave of innovation in mobile communications and drive long-term growth. Additionally, the companies have signed a definitive agreement for Twilio to invest up to $750M million cash in Syniverse and become a significant minority owner of the Company. The Carlyle Group, Syniverse's current majority owner, will maintain its majority interest in Syniverse. Through this partnership, Syniverse will benefit from Twilio's breadth of experience serving Enterprise customers to capitalize on the next wave of growth in mobile communications. Syniverse will be even better positioned to serve its core Carrier customers and support continued innovation, customer service and long-term growth. Syniverse and Twilio will enter into a wholesale agreement whereby Syniverse will process, route and deliver application-to-person messages originating and/or terminating between Twilio's customers and mobile network operators. James Attwood, Executive Chairman of Syniverse said, "We are thrilled to enter into this partnership with Twilio, which we believe will accelerate our next phase of growth as the world's most connected company. The partnership will provide Syniverse access to Twilio's extensive enterprise and API services expertise, creating opportunities to continue to build on Syniverse's highly innovative product portfolio that helps mobile network operators and enterprises make communications better for their customers." "Twilio's vision is to build the world's leading customer engagement platform. As messaging becomes a preferred way for consumers to communicate with brands, Syniverse helps remove the complexity of the interconnected telecommunications ecosystem, so Twilio can provide best-in-class messaging services to its customers globally," said Chee Chew, Chief Product Officer at Twilio. "We have long been a Syniverse customer and are pleased to expand our relationship to provide reliable, scalable and rich two-way messaging for businesses and their customers."

08:07 EST TopBuild to acquire American Building Systems, terms not disclosed - TopBuild has entered into an agreement to acquire all of the assets and business of the American Building Systems Group of Companies. ABS, a residential insulation and distribution business founded in 1982, has 34 branches that primarily services the eastern United States. Major operations exist in Georgia, Virginia, the Carolinas, Florida, Massachusetts and New Jersey. Approximately 94% of ABS' $144 million of annual revenue is from installation of insulation and other building products, with the remaining 6% from distribution. The transaction, which has been approved by TopBuild's Board of Directors, is subject to customary closing conditions, including expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The Company expects the transaction to close early in the second quarter of 2021.

08:05 EST Rhythm Pharmaceuticals announces 2021 anticipated milestones - Rhythm expects to achieve the following milestones in 2021: Commercial and Regulatory Milestones: Make IMCIVREE commercially available in the United States for obesity due to POMC, PCSK1 and LEPR deficiencies in the first quarter of 2021. Obtain regulatory approval from the European Commission and make IMCIVREE commercially available in Europe in POMC, PCSK1 and LEPR deficiency obesities in the second half of 2021. Complete regulatory submissions to both the FDA and the EMA seeking marketing authorization for setmelanotide for the treatment of obesity in patient with BBS in the second half of 2021. Clinical Milestones: Initiate a Phase 2 clinical trial of setmelanotide in hypothalamic obesity in the first half of 2021. Announce new top-line data from the ongoing exploratory Phase 2 Basket Study evaluating setmelanotide in MC4R-recusable patients in the first half of 2021. Announce full data from the pivotal Phase 3 trial evaluating setmelanotide in Bardet-Biedl and Alstrom Syndromes in the first half of 2021. Initiate a Phase 2 clinical trial of setmelanotide in pediatric patients aged two to six years old in the second half of 2021. Pending FDA feedback, initiate a pivotal Phase 3 MC4R pathway trial of setmelanotide in patients with HET obesity, as well as SRC1 and SH2B1 deficiency obesities, in the second half of 2021. Initiate an expanded Phase 2 Basket Study of setmelanotide in patients with variants in one of 31 additional genes with strong or very strong MC4R pathway relevance in the second half of 2021. Initiate a Phase 3 potentially registration-enabling trial for the weekly formulation of setmelanotide in the second half of 2021.

08:02 EST TransDigm to divest ScioTeq and TREALITY businesses to OpenGate for $200M - TransDigm Group announced it has entered into a definitive agreement to sell its ScioTeq and TREALITY Simulation Visual Systems businesses to OpenGate Capital in a transaction valued at approximately $200M. ScioTeq and TREALITY were acquired by TransDigm in March 2019 as part of the Esterline Technologies acquisition. The businesses develop and manufacture advanced visualization solutions primarily for the global defense, air traffic control, and security end markets. ScioTeq and TREALITY have approximately 450 employees and operate primarily from Belgium, with secondary locations in the United States. The businesses generated revenues of approximately $135M for the fiscal year ended September 30, 2020. The divestiture, which is subject to regulatory approvals and customary closing conditions, is expected to be completed during the third quarter.

07:54 EST VSE Corp. acquires HAECO Special Services - VSE Corporation announced that it has acquired HAECO Special Services from HAECO Airframe Services, a division of HAECO Americas, in an all cash transaction. HSS is a leading provider of fully integrated MRO support solutions for military and government aircraft. HSS offers scheduled depot maintenance, contract field deployment and unscheduled drop-in maintenance for a U.S. Department of Defense contract specifically for the sustainment of the U.S. Air ForceKC-10 fleet. The experienced workforce of HSS includes nearly 280 employees operating from two hangar locations in Greensboro, North Carolina. "We are excited to welcome the outstanding HAECO Special Services team to VSE," stated John Cuomo, President and CEO of VSE Corporation. "This transaction further expands our value-added suite of MRO solutions available to military customers, while positioning us to capitalize on higher-margin technical service opportunities. HSS' operating income and cash flow profile, strong backlog and contract diversification efforts are highly complementary to our Federal & Defense Services business and strategy, positioning us to further support military and government customers with on-demand MRO support for aging, mission-critical assets."

07:51 EST Flexion announces FDA clearance for FX301 IND application - Flexion Therapeutics announced the U.S. Food and Drug Administration cleared the Investigational New Drug application for FX301, a locally administered NaV1.7 inhibitor known as funapide, formulated for extended-release in a thermosensitive hydrogel. The selective pharmacology of funapide holds the potential to provide effective non-opioid pain relief for at least 3 to 5 days, while preserving extremity motor function which is typically compromised by local anesthetic peripheral nerve block. The FDA's clearance of the IND was supported by key preclinical data developed by Flexion and extensive clinical data associated with previous clinical trials investigating funapide in other indications. In a validated preclinical model of post-operative pain, FX301 administered as a peripheral nerve block demonstrated analgesic effect beginning at 1 hour post-dosing compared to placebo and significantly greater analgesic effect compared to liposomal bupivacaine at 36 hours post-dosing. Data from the study also indicated that treatment with FX301 did not significantly affect total walking distance in animals at 2 and 24 hours post-injection, whereas animals treated with liposomal bupivacaine experienced a significant reduction in total walking distance at those time points. Flexion plans to initiate a Phase 1b proof of concept clinical trial of FX301 administered as a popliteal fossa block in patients undergoing bunionectomy and expects to treat the first patient in the first half of this year. Topline results from the trial are anticipated in late 2021.

07:51 EST Stratasys expects Q1 revenue to track similarly to 1Q20 - Sees Q2 revenue up mid-teens percentage range. Sees FY21 operating expense $25M higher than FY20. Sees FY21 capital expenditures $24M-$30M.

07:47 EST Satsuma Pharmaceuticals announces $80M private placement financing - Satsuma Pharmaceuticals announced that it has agreed to sell 14,084,507 shares of its common stock to certain institutional investors in a private investment in public equity financing. The Company anticipates gross proceeds from the PIPE will be approximately $80 million, before deducting fees to the placement agents and other estimated offering expense payable by the Company, based on the offering price of $5.68 per share, the last reported sale price of our common stock on The Nasdaq Global Market on February 26, 2021. The financing was led by Commodore Capital and New Enterprise Associates, L.P. with participation from new and existing investors including RA Capital Management, Vivo Capital, Samlyn Capital, Surveyor Capital, Aspire Capital Fund, funds managed by Ghost Tree Capital Group, LP, Point72 Asset Management and Logos Capital as well as Satsuma co-founder, Shin Nippon Biomedical Laboratories, Ltd. The financing is subject to standard closing conditions and the Company anticipates the closing to occur on March 3, 2021. In addition the financing was executed in compliance with applicable Nasdaq rules and priced at the "Minimum Price".

07:46 EST Colliers to settle incentive arrangement, eliminate dual voting structure - Colliers International Group announced that it has entered into an agreement with Jay S. Hennick, the Company's Chairman & CEO and largest voting shareholder, pursuant to which disinterested holders of Colliers' Subordinate Voting Shares will be given an opportunity to approve a transaction to settle the Management Services Agreement, including the long-term incentive arrangement, originally entered into on February 1, 2004, between the Company, Mr. Hennick and Jayset Management CIG Inc., a corporation controlled by Mr. Hennick. In addition, the Transaction will establish an orderly timeline for the elimination of Colliers' dual class voting structure by no later than September 1, 2028. The LTIA included in the MSA with Mr. Hennick was established seventeen years ago to replace all stock options and other compensation entitlements to which he would otherwise be entitled, a plan consistent with similar arrangements in place at the time designed to incentivize entrepreneurial founders/CEOs to create long-term value for shareholders. The arrangement achieved the intended result, with the market capitalization of Colliers increasing by over US$3.8 billion since 2004, representing an annualized compounded return to shareholders of approximately 18% to the end of 2020. Over the past several years, the Board of Directors of Colliers regularly considered the financial and other implications of continuing with the MSA, including the LTIA, as the Company continued to grow. In late 2020, the members of the Board of Directors indicated to Mr. Hennick that they wished to evaluate the potential termination of the LTIA and thereby limit the future growth in value of this arrangement and to allow the Company to complete certain types of transactions, including additional equity offerings without being impacted by the LTIA. Mr. Hennick suggested he was prepared to receive a proposal from Colliers in this regard provided it was fair and in the best interests of all concerned. As a result, the Board of Directors established a special committee. Following a rigorous independent review process, including receipt of advice from independent legal and compensation advisors, the Special Committee unanimously recommended the Transaction to the Board of Directors, who unanimously approved it. As part of the Transaction: Colliers will acquire all of the shares of HennickCo, the recipient of all fees and other entitlements under the MSA, for a purchase price determined with reference to the LTIA formula provided in the MSA, and thereafter terminate the existing MSA; Colliers and Mr. Hennick will enter into a new five-year management services agreement, with mutual one-year renewal options thereafter pursuant to which Mr. Hennick will continue to provide services to Colliers as, at his option, the Chief Executive Officer and/or Executive Chairman. The New MSA will be substantially similar to the current MSA, except that there will be no entitlement to a LTIA, stock options or other equity-linked compensation; Mr. Hennick and Henset Capital Inc.will enter into a new trust agreement relating to the Multiple Voting Shares controlled by them, providing that such Multiple Voting Shares will convert into Subordinate Voting Shares on a one-for-one basis and for no additional consideration or premium upon the earliest to occur of: The date that the sum of the number of Multiple Voting Shares and Subordinate Voting Shares beneficially owned by Henset Capital Inc. and Mr. Hennick, together with their associates and affiliates, is less than 4,000,000; 24 months after the date the New MSA is terminated as a result of Mr. Hennick's death, disability, voluntary resignation or the occurrence of certain other specific events contained in the New MSA; and September 1, 2028; Colliers will: pay US$95.0 million in cash in satisfaction of 20% of the purchase price; and issue a total of 3,572,858 Subordinate Voting Shares in satisfaction of 80% of the purchase price. The total purchase price was determined by applying the formula provided in the existing MSA for the LTIA using a price of US$106.40 per share. The Transaction is subject to the approval of a majority of the disinterested holders of Subordinate Voting Shares at an Annual and Special Meeting of Shareholders to be held on April 14, 2021 at 11:00 a.m.. It is also subject to customary closing conditions, including lender approval and receipt of all other third party and regulatory consents and approvals, including from the Toronto Stock Exchange and NASDAQ.

07:41 EST Cerecor appoints Schond Greenway as CFO - Cerecor (CERC) announced the appointment of Schond Greenway as CFO, effective March 1, 2021. Chris Sullivan, who has served as the Company's Interim CFO for the past year, will continue with the Company as its CAO. Greenway joins Cerecor from Mesoblast (MESO), an allogeneic cellular medicines company, where he served as Vice President, Investor Relations. In connection with the appointment of Mr. Greenway and in accordance with the terms of his employment agreement with the Company, Cerecor's Board of Directors approved the grant to Mr. Greenway of a non-qualified stock option awarded to purchase 500,000 shares of its common stock, vesting over four years, with a twelve-month cliff, such that the first 25% will vest on the first anniversary following Mr. Greenway's start date with the Company, and the remainder will vest in equal monthly installments over the following three years, in each case, subject to continued employment with the Company through the applicable vesting date.

07:38 EST Sonic Foundry CFO Kelsy Boyd resigns - Sonic Foundry announced that Kelsy Boyd, the company's CFO has chosen to step away from the business for personal reasons. Boyd is committed to an organized transition of her duties through April 2, 2021. The company has appointed long-standing former employee Ken Minor, who served as Sonic Foundry CFO from 1997 to 2020, as interim CFO. Minor will work closely with CEO Joe Mozden Jr. to oversee Sonic Foundry's financial strategy.

07:37 EST VBL Therapeutics announces patient dosing in VB-111 trial - VBL Therapeutics announced that patient dosing has been initiated in a Phase 2 clinical trial investigating ofranergene obadenovec for the treatment of recurrent glioblastoma multiforme. The study is sponsored by Dana-Farber Cancer Institute and is being conducted through a collaboration between VBL and seven leading neuro-oncology medical centers in the U.S. The Phase 2 study is enrolling patients with rGBM who are scheduled to undergo a second surgery. VB-111 will be administered either before and after surgery or after surgery only and each arm will be compared to a standard of care control arm. In addition to endpoints of progression-free survival at 6 months and overall survival, collection of tumor specimens will allow important analysis of the activity of VB-111 within the tumor and will evaluate its effect on the immune system in this immunologically 'cold' tumor.

07:36 EST Lion Group announces sponsorship of SPAC company - Lion Group announced that one of its subsidiaries, Lion Wealth Management Limited, will cooperate with Constant Epoch Technology Development Limited, an investment and R&D company focusing on innovative technology sector, and Ruoxi Ltd., a company holding various investments in internet, technology, finance, healthcare and other industries, to form a SPAC company -- Skyline I Acquisition Corp. Wilson Wang, CEO of Lion, will be the CEO and Director of Skyline I Acquisition. Yipeng Huang, co-founder and CFO of Constant Epoch, will serve as a Director of Skyline I Acquisition. Jun Yang, founder and board chairman of Ruoxi, will also serve as a Director of Skyline I Acquisition.

07:35 EST Mateon Therapeutics, Windlas publish PulmoHeal clinical data - Mateon Therapeutics and Windlas Biotech announced the publication of ARTI-19 in peer-reviewed journals. ARTI-19 is "A Prospective, Randomized, Multi-center, Open-label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19".

07:32 EST MannKind announces proposed private placement of convertible senior notes - MannKind Corporation announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2026 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. MannKind also intends to grant the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $22.5 million aggregate principal amount of notes. The notes will be general unsecured obligations of MannKind and will accrue interest payable semiannually in arrears. Upon conversion, MannKind will pay or deliver, as the case may be, cash, shares of MannKind's common stock or a combination of cash and shares of MannKind's common stock, at its election. The interest rate, initial conversion rate and other terms of the notes will be determined at the time of pricing of the offering. MannKind intends to use the net proceeds from this offering for working capital and other general corporate purposes, including a Phase 3 clinical trial of Afrezza in pediatric subjects and further development of product candidates in MannKind's pipeline. MannKind may use a portion of the proceeds from this offering to pay down a portion of existing debt or for acquisitions or strategic investments in complementary businesses or technologies, although MannKind does not currently have any plans for any such debt repayment, acquisitions or investments.

07:29 EST Satsuma Pharmaceuticals plans to begin STS101 Phase 3 trial in mid-2021 - Satsuma Pharmaceuticals announced an update to the development plan for STS101, an investigational acute treatment for migraine. The updated STS101 development plan includes a new Phase 3 efficacy trial, which the Company anticipates initiating in mid-2021, with topline results expected in the second half of 2022. The new Phase 3 trial takes into account findings from the EMERGE pivotal study in which STS101 showed numerical differences in favor of STS101 5.2 mg and 3.9 mg versus placebo but did not achieve statistical significance versus placebo on the co-primary endpoints of freedom from pain and most bothersome symptom at two hours post-administration. In addition, the Company plans to explore dose strengths greater than 5.2 mg by conducting a Phase 1 trial in the second quarter of 2021 to evaluate the pharmacokinetics, safety, and tolerability of STS101 5.2 mg and two higher dose strengths. The Company plans to select the STS101 dose strength to utilize in its next Phase 3 efficacy trial based on the results of this Phase 1 trial. Satsuma also announced that it has entered into a securities purchase agreement with existing and new investors for an $80M private placement financing. The Company believes that net proceeds from the private placement financing, together with its existing cash, cash equivalents and short-term investments of $68.2M as of December 31, 2020, will be sufficient to fund company operations into the second half of 2023. The Company is holding a conference call this morning to discuss its updated STS101 development plan, as well as preliminary results to date from the ongoing open-label ASCEND long-term safety trial of STS101 5.2 mg, and a synopsis of key EMERGE trial findings. On September 10, 2020, the Company announced topline results from the EMERGE Phase 3 efficacy trial of STS101. As detailed in the table below, although topline data showed numerical differences in favor of STS101 3.9 mg and 5.2 mg versus placebo on the pre-specified co-primary endpoints of freedom from pain and freedom from most bothersome symptom at two hours post-administration, these differences did not achieve statistical significance for either dose strength. Both dose strengths of STS101 did, however, demonstrate significant effects on both freedom from pain and most bothersome symptom endpoints by three hours post-dose and later time points. Consistent with the safety and tolerability results to date observed in other STS101 clinical trials, including the ongoing ASCEND open-label, long-term safety trial, both STS101 dose strengths were well-tolerated in the EMERGE trial, with low adverse event rates and no drug-related serious adverse events reported. Based on its analyses, the Company believes it has identified, and is taking steps to address in the new Phase 3 efficacy trial, the key reasons that STS101 did not achieve statistical significance versus placebo on the co-primary endpoints in the EMERGE trial. As of February 23, 2021, the Company has enrolled more than 275 subjects in its ongoing ASCEND open-label, long-term safety trial who have treated a total of more than 2,200 migraine attacks with STS101 5.2 mg. STS101 5.2 mg has been been well-tolerated to date in the ASCEND trial, with low adverse event rates and no drug-related serious adverse events reported. In addition, the Company believes that, based on the preliminary results from the ASCEND open-label, long-term safety trial, STS101 5.2 mg demonstrates anti-migraine activity at the two-hour time point. Anticipated STS101 development milestones: Second Quarter 2021 - Complete Phase 1 safety and pharmacokinetic study with STS101 5.2 mg and two higher dose strengths. Mid-2021 - Initiate second STS101 Phase 3 efficacy trial. Second Half 2022 - Read out topline results from second Phase 3 efficacy trial. Fourth Quarter 2022 - File STS101 NDA .

07:27 EST NTN Buzztime board urges shareholders to vote for proposed merger, asset sale - The board of directors of NTN Buzztime unanimously urges NTN's stockholders to vote FOR ALL the proposals to be voted on at the March 15 special meeting of stockholders, all of which relate to the proposed merger involving NTN and Brooklyn ImmunoTherapeutics and the proposed sale of NTN's assets to eGames.com Holdings.

07:25 EST Agios Pharmaceuticals submits supplemental NDA to FDA for TIBSOVO - Agios Pharmaceuticals announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration for TIBSOVO as a potential treatment for patients with previously treated isocitrate dehydrogenase 1 mutated cholangiocarcinoma. Agios has requested priority review for the application, which, if granted, could result in a six-month review process. The sNDA submission is supported by data from the ClarIDHy study, the first and only randomized Phase 3 trial for previously treated IDH1-mutated cholangiocarcinoma. Data from the study were previously presented at the European Society for Medical Oncology Congress, held in September 2019 in Barcelona, Spain, and published in The Lancet Oncology on May 13, 2020. A final analysis of the data was featured in an oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium on January 17, 2021.

07:23 EST Dana acquires Pi Innovo LLC, terms not disclosed - Dana announced that it has acquired Pi Innovo LLC, a leader in embedded software solutions and electronic control units to support the light vehicle, commercial vehicle, and off-highway markets. Dana previously held a non-controlling interest.

07:21 EST Athenex announces key anticipated future milestones - Key Anticipated Future Milestones: Request a meeting with the FDA to discuss and align on next steps to obtain approval for oral paclitaxel plus encequidar in metastatic breast cancer; Identify and undertake appropriate adjustments for the company pending the outcome of the FDA meeting; Begin expansion portion of the oral paclitaxel plus pembrolizumab Phase I trial; Present the oral paclitaxel plus pembrolizumab Phase I trial data at a medical conference in 2021; Anticipate EMA approval of Klisyri in 2021; TCR-T NY-ESO-1 IRB approval and initiate P1 trial enrollment in 1H 2021; Anticipate results from the I-SPY 2 trial of oral paclitaxel plus anti PD-1 in 2022.

07:17 EST Avrobio receives orphan drug designation for AVR-RD-04 from EC - Avrobio announced that the European Commission, or EC, has granted orphan drug designation for AVR-RD-04, the company's investigational gene therapy for the treatment of cystinosis. AVR-RD-04 consists of the patient's own hematopoietic stem cells, genetically modified to express cystinosin, the protein that is deficient in patients with cystinosis. AVR-RD-04 is currently being evaluated in a Phase 1/2 clinical trial sponsored by Avrobio's academic collaborator at the University of California, San Diego.

07:15 EST Hologic acquires Diagenode for $159M, sees accretion after FY22 - Hologic announced that it has acquired Diagenode, a privately held, European developer and manufacturer of molecular diagnostic assays and epigenetics products, for approximately $159M, subject to working capital and other customary closing adjustments. Diagenode offers more than 30 real-time PCR tests that are CE-marked for the detection of bacteria, parasites and viruses involved in sexually transmitted infections, respiratory diseases, meningitis and gastroenteritis. Diagenode previously collaborated with Hologic to develop Panther Fusion assays for group B Streptococcus and Bordetella. Diagenode is also playing a role in epigenetics with a portfolio of devices, kits, reagents, antibodies and services to aid in the analysis of DNA and RNA. Diagenode generated more than $30M of revenue in the last 12 months. The acquisition is expected to be approximately break-even to Hologic's non-GAAP earnings per share through fiscal 2022, and accretive thereafter.

07:13 EST Arvinas announces anticipated milestones, expectations - Anticipated Milestones and Expectations: ARV-471: Completion of the Phase 1 dose escalation 1H21; Presentation of completed Phase 1 dose escalation data 2H21; Announcement of safety data from the Phase 1b trial in combination with Ibrance 2H21; Initiation of a window of opportunity study in adjuvant breast cancer 2H21; Initiation of a combination trial of ARV-471 and another targeted therapy in 2L/3L metastatic breast cancer 2H21. ARV-110: Completion of the Phase 1 dose escalation 1H21; Presentation of completed Phase 1 dose escalation data 2H21; Announcement of interim data from the ARDENT Phase 2 dose expansion at 420 mg 2H21; Initiation of combination trial with standards-of-care 2021. Other Clinical Milestones: Initiation of first-in-human study of ARV-766, an androgen receptor degrader with a differentiated profile from ARV-110, in patients with metastatic castration-resistant prostate cancer 1H21.

07:10 EST Flowserve supports Pfizer in production of COVID-19 vaccine - Flowserve (FLS) announced it is providing pumps, valves and seals to Pfizer (PFE) to support production of its COVID-19 vaccine. During the engineering runs of vaccine production Pfizer needed support to replace a mechanical mixer seal on its COVID-19 vaccine production line. The Flowserve Kalamazoo, Michigan team expedited the rebuild of this equipment. Additionally, Flowserve through its channel partner, Corrosion Fluid Products, is providing Pfizer with a cryogenic valve application to support their expanded production capabilities of the COVID-19 vaccine. The Flowserve Cookeville, Tennessee facility will supply Pfizer with more than 200 Worcester cryogenic ball valves that can handle the rigorous temperature requirements needed in supporting the mass production of the COVID-19 vaccine. And finally, Flowserve's Chesapeake, Virginia and Itzehoe, Germany pump manufacturing facilities are providing pumps to Pfizer for both their North American and European vaccine production.

07:07 EST Amicus sees FY21 total Galafold revenue $300M-$315M - Double-digit revenue growth in 2021 is expected to be driven by continued operational growth and commercial execution across all major markets, including the U.S., EU, U.K. and Japan. Non-GAAP operating expense guidance for the full-year 2021 is $410 million to $420 million, driven by continued investment in the global Galafold launch, AT-GAA clinical studies and pre-launch activities, and advancing our gene therapy pipeline. Cash, cash equivalents, and marketable securities totaled $483.3 million at December 31, 2020. Based on current operating models, the company believes that the current cash position, which includes the net proceeds from the 2020 Senior Secured Term Loan, and expected future revenues are sufficient to fund the company's operations and ongoing research programs through to self-sustainability.

07:05 EST Cannae Holdings announces three year, 10M share repurchase program - Cannae Holdings announced that its Board of Directors has authorized a three-year stock repurchase program, effective February 26, under which the Company may repurchase up to 10M shares of its common stock. Purchases may be made from time to time in the open market at prevailing prices or in privately negotiated transactions through February 26, 2024. The repurchase program does not obligate the Company to acquire any specific number of shares and may be suspended or terminated at any time. William P. Foley, II, Chairman of Cannae, commented, "Recent discussions with key investors reinforced my belief that Cannae stock is significantly undervalued. In fact, it's trading well below book value despite the recent impressive investments by Cannae, as outlined in our most recent report to shareholders. Repurchases around these price levels actually increase book value per share."

07:04 EST Axsome Therapeutics announces 2021 anticipated milestones - Anticipated Milestones NDA Submissions: AXS-07 for the acute treatment of migraine, submission early 2Q 2021. Clinical Trial Readouts: Phase 2 MERIT trial of AXS-05 in TRD, topline data 2H 2021. Clinical Trial Initiations: Phase 3 trial of AXS-12 in the treatment of narcolepsy 2Q 2021. FDA Meetings: AXS-14 for fibromyalgia 2Q 2021; AXS-05 for smoking cessation 3Q 2021.

06:56 EST Tyson Foods to vaccinate thousands of Iowa workers - Tyson Foods will offer free, onsite COVID-19 vaccinations to thousands of frontline team members at its Iowa plants this week. The vaccines are being provided in conjunction with local health departments across the state of Iowa, where food processing workers are among the priority group now eligible for vaccination. "We've been working with Matrix Medical, Hy-Vee and health department officials across Iowa to prepare for this moment and we're ready," said Tom Brower, senior vice president of Health and Safety for Tyson Foods. "We're pleased to offer our team members convenient access to the vaccine, and we appreciate the state of Iowa recognizing the essential role they play in feeding the world." Tyson Foods officials expect many of the company's 13,000 Iowa employees to be vaccinated during vaccination events later this week at or near company facilities in Columbus Junction, Council Bluffs, Independence, Perry, Sioux City, Storm Lake and Waterloo. More than 2,000 of the company's U.S employees were recently vaccinated either at onsite events or through an external source. Approximately 800 team members were vaccinated February 19 and 20 at Tyson's Joslin, Ill., beef plant.

06:53 EST Rekor Systems comments on offer to purchase Iteris - Rekor Systems (REKR) announced that on February 20, it had advised Iteris (ITI) that it was prepared to offer to purchase all of Iteris' outstanding common stock. The offer to Iteris was for a combination of cash and common stock subject to confirmatory diligence and approval of both boards of directors. On February 26, Rekor was advised that the board of directors of Iteris "has decided at this time the combination of the two companies would not be in the best interest of [Iteris'] shareholders." "Since announcing our active consideration of potential merger partners several weeks ago, we've received a number of inquiries about a possible combination with Iteris from Rekor shareholders and investors. Obviously, we haven't been in a position to respond," said Robert Berman, Rekor CEO. "We are clearly disappointed with their swift rejection and wanted to avoid any inappropriate speculation."

06:47 EST Wex expands presence in Europe - Wex announced its agreement with OMV expanding its presence within Europe. Wex will implement its technology platform to manage OMV's fuel card program across ten markets within Europe. The implementation is expected to be completed within the next two years.

06:46 EST Merck: FDA accepts gefapixant New Drug Application for review - Merck announced that the U.S. FDA has accepted for review the company's New Drug Application for gefapixant, an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough or unexplained chronic cough in adults. This application for gefapixant will be discussed at an upcoming advisory committee meeting. No date has been set yet. The FDA has set a Prescription Drug User Fee Act, or target action date, of Dec. 21, 2021.

06:37 EST Rocket Lab USA , Vector Acquisition announce merger pact - Rocket Lab USA and Vector Acquisition Corporation announced that they have entered into a definitive merger agreement that will result in Rocket Lab becoming a publicly traded company. The transaction is estimated to be completed in Q2 2021 and, at that time, Vector will change its name to Rocket Lab USA, and the combined company will trade under the Nasdaq ticker symbol "RKLB." On March 1, Rocket Lab entered into a definitive merger agreement with Vector. The transaction reflects an implied pro forma enterprise value of $4.1B for Rocket Lab, representing 5.4x 2025 projected revenue of approximately $750M. The transaction is expected to result in pro forma cash on the balance sheet of approximately $750M through the contribution of existing cash estimated to be on Rocket Lab's balance sheet prior to close, up to $320M of cash held in Vector Acquisition Corporation's trust account (assuming no redemptions by Vector's public shareholders), and a concurrent approximately $470M PIPE of common stock, priced at $10.00 per share and led by Vector Capital, BlackRock and Neuberger Berman, among other top-tier institutional investors. The transaction, which has been unanimously approved by the Boards of Directors of Rocket Lab and Vector, is subject to approval by Vector's shareholders and other customary closing conditions. Following the closing of the transaction, the Company will continue to be led by Founder and CEO Peter Beck. Alex Slusky, CEO of Vector and CIO and Founder of Vector Capital, will join Rocket Lab's Board of Directors alongside Sven Strohband of Khosla Ventures, David Cowan of Bessemer Venture Partners, Matt Ocko of DCVC and Mike Griffin, independent director.

06:34 EST Cardlytics to acquire Dosh for $275M in cash and stock - Cardlytics announced its planned acquisition of Dosh, a cash-back offers platform, for $275M in cash and stock. Founded in 2016, Dosh is best known for creating a consumer app that provides cash back for millions of consumers from thousands of merchants. This transaction is expected to close later this quarter.

06:33 EST Spire Global to go public through merger with NavSight Holdings - Spire Global, a global provider of space-based data and analytics, and NavSight Holdings Inc., a special purpose acquisition company, announced they have entered into a definitive merger agreement for a business combination that would result in Spire becoming a publicly listed company. The Board of Directors of each of Spire and NavSight have unanimously approved the transaction "Proposed Transaction." The Proposed Transaction will require the approval of the stockholders of Spire and NavSight, and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The Proposed Transaction is expected to close in summer of 2021. Assuming no redemptions by NavSight stockholders, the Proposed Transaction is expected to deliver up to $475M of gross proceeds, including the contribution of up to $230M of cash held in NavSight's trust account. The Proposed Transaction is further supported by a $245M fully committed PIPE anchored by Tiger Global Management, BlackRock Advisors, Hedosophia, Jaws Estates Capital, and Bloom Tree Partners. Spire stockholders will retain 100% of their equity holdings in the combined company. Spire's existing stockholders will hold approximately 67% of the fully diluted shares of common stock immediately following the closing of the business combination, assuming no redemptions by NavSight's existing public stockholders.

06:31 EST Spire Global to go public through merger with NavSight Holdings

06:21 EST New Home Company acquires Epic Homes - The New Home Company announced its expansion into Denver, Colorado with the acquisition of Epic Homes, a unique and innovative homebuilder with a strong, well-established presence in the market. Epic President and Founder Christina Presley will remain on board as President of Epic Homes, a newly formed homebuilding division of The New Home Company. New Home assumed Epic's backlog of 102 homes valued at approximately $100M as of the closing date of February 26. In addition, New Home assumed control of Epic's land assets which include 294 owned and controlled lots, three active communities and one soon-to-be-opened community. The average selling price of Epic's communities range from $600,000-$1.4M.

06:18 EST Descartes Systems acquires QuestaWeb for approximately $36M - Descartes Systems announced that it has acquired QuestaWeb, a provider of foreign trade zone and customs compliance solutions. QuestaWeb is headquartered in Clarke, New Jersey. Descartes acquired QuestaWeb for approximately $36M, satisfied from cash on hand.

06:15 EST Tanzanian Gold names Michael Leonard as CFO - Tanzanian Gold (TRX) is pleased to announce and welcome Michael Leonard, CPA, CA as CFO of Tanzanian Gold. Leonard has had a distinguished career as a financial leader in the gold industry with broad, progressive experience in investor relations and corporate global finance. He had an impressive, respected and esteemed career of more than 17 years in financial leadership at Barrick Gold (GOLD).

06:12 EST Core-Mark announces new three-year, $375M shareholder return plan - Core-Mark's Board of Directors approved a new three-year, $375M shareholder return plan supporting increased share buy-backs and growth in the dividend. This new plan replaces the previous $60M share repurchase program.

06:09 EST President Biden tells Amazon not to meddle in union vote - President Joe Biden has demanded that Amazon not intimidate or threaten workers who are voting to join a union at an Alabama warehouse, saying in a video posted to Twitter on Sunday evening "The choice to join a union is up to the workers - full stop." "Let me be really clear," Biden said. "It's not up to me to decide whether anyone should join a union. But let me be even more clear: it's not up to an employer to decide that either." Reference Link

06:07 EST CMC Materials to acquire International Test Solutions for about $125M in cash - CMC Materials announced that it has entered into an agreement to acquire International Test Solutions, a leader in the design and production of innovative, high-performance consumables used to optimize critical semiconductor testing processes. Headquartered in Reno, Nevada and supplying to semiconductor manufacturers globally, ITS will become part of the company's Electronic Materials business segment. CMC Materials has agreed to acquire ITS for approximately $125M in cash, which is expected to be funded by cash on hand, and expects to complete the transaction in April, subject to customary closing conditions, including post-closing adjustments, and regulatory approvals.

06:06 EST CAE to acquire L3Harris Technologies military training business for $1.05B - CAE (CAE) announced that it has entered into a definitive agreement with L3Harris Technologies (LHX) to acquire L3Harris' military training business for $1.05B, subject to customary adjustments. The acquisition value represents approximately 13.5 times the L3Harris military training business estimated adjusted 2020 EBITDA or approximately 10 times, including cost synergies, which are expected to reach a range of $28M to $35M annually by the end of the second year following closing of the acquisition. The acquisition is expected to be low-teens percentage EPS accretive to CAE in the first full year post closing, including expected cost synergies. The closing of the acquisition is expected in the second half of calendar year 2021, subject to regulatory approvals and other customary closing conditions. Upon closing, the L3Harris military training business would operate under CAE USA, headquartered in Tampa, Florida. The acquisition and other related transaction costs are to be funded through the issuance of $550M aggregate amount of subscription receipts to two institutional investors on a private placement basis as well as other currently available liquidities. The private placements are supported by a $375M investment by Caisse de depot et placement du Quebec, a Canada-based global institutional investor, and a $175M investment by GIC Private. An aggregate of 22,400,000 subscription receipts will be issued at a price of C$31.25 per subscription receipt, for gross proceeds of approximately $550M. Each subscription receipt will entitle the holder to receive one common share of CAE as well as a commitment fee upon and subject to closing of the acquisition.

05:43 EST Baidu, Huaneng enter MoU for energy industry development - Baidu and China Huaneng recently signed a memorandum of understanding, or MoU, aimed at driving the transformation of the energy industry. Baidu will leverage its capabilities in AI-powered new infrastructure to help Huaneng closely integrate the digital economy with the energy and power industry. Under the terms of the MoU, Baidu and Huaneng will pursue a multi-faceted partnership encompassing information technology, digital technology, and other related areas. The two companies will jointly develop a new generation automated and intelligent financial shared services platform, as well as cooperate to apply AI and big data technologies to the energy and power field. Additionally, the partnership will strive to provide society with energy-related data services that are more digitized, intelligent, and connected to the Internet, which will drive the intelligent upgrading of China's energy industry.

05:23 EST Chevron announces investment in Baseload Capital - Chevron announced an investment in Baseload Capital, a Sweden-based private investment company focused on development and operation of low-temperature geothermal and heat power assets. This investment round also includes existing Baseload Capital investors. The Baseload investment follows last month's announcement of funding for Eavor and expands Chevron's capacity to gain insight into geothermal innovations such as low-temperature power generation and closed-loop geothermal technologies. Chevron and Baseload are planning potential pilot projects to test new technology. Baseload Capital currently operates in Japan, Taiwan, Iceland, and the United States. As Baseload develops in these regions and expands to new markets, Chevron and Baseload will look for commercial geothermal and heat power opportunities in additional Chevron operations.

05:16 EST Accenture acquires Cirrus, terms undisclosed - Accenture (ACN) has acquired Cirrus, a UK headquartered leadership and talent consultancy. Cirrus joins Accenture's talent and organization/human potential team and "strengthens" its development and coaching capabilities for leaders seeking business transformation. Terms of the transaction were not disclosed. The company said, "With 70 experts located in the U.K. and Australia serving global clients, Cirrus blends leadership, talent, and engagement expertise to assess and develop leaders - creating behavioural change and implementing agile ways of working to unlock their potential. Cirrus has a proven track record of delivering business impact through bespoke leadership and team development solutions run via virtual, face-to-face and digital channels."

05:09 EST Polaris to debut 2022 electric Ranger utility side-by-side in late December - Polaris unveiled plans to debut an all-new 2022 electric Ranger utility side-by-side in late December, advancing the company's strategic rEV'd up electrification strategy. This full-size Ranger is the first electric vehicle Polaris developed through its powersports industry-exclusive partnership with Zero Motorcycles, which the two companies announced last September. The company expects the new electric Ranger to start arriving in dealerships in early 2022. Design and development efforts for the all-new electric Ranger are underway in Wyoming, Minnesota., with manufacturing for North American vehicles to take place at Polaris' facility in Huntsville, Alabama.

04:55 EST WSFS Financial to replace Cleveland-Cliffs in S&P 600 at open on 3/1